Cover Image
市場調查報告書

Acucela Inc.:產品平台分析

Acucela Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 192434
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Acucela Inc.:產品平台分析 Acucela Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月11日 內容資訊: 英文 27 Pages
簡介

Acucela Inc.是據點在美國西雅圖,臨床階段的生物科技企業。該公司,致力開發為了治療威脅視力的眼疾、延遲惡化的劃時代治療藥。並且與全世界各種領域的機關合作進行眼科調查及證實臨床開發可能性的研究開發。

本報告提供Acucela Inc.的治療藥開發平台的現狀及各開發階段比較分析、藥物標的、作用機制、給藥途徑、各分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

Acucela Inc.的基本資料

  • Acucela Inc.概要
  • 主要資訊
  • 企業資料

Acucela Inc.:R&D概要

  • 主要的治療範圍

Acucela Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Acucela Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Acucela Inc.:藥物簡介

  • emixustat hydrochloride
  • Small Molecule for Retinitis Pigmentosa
  • Small Molecule for Retinopathy of Prematurity
  • Small Molecule for Stargardt Disease

Acucela Inc.:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Acucela Inc.:最近的開發平台趨勢

Acucela Inc.:暫停中的計劃

Acucela Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06847CDB

Summary

Global Markets Direct's, 'Acucela Inc. - Product Pipeline Review - 2015', provides an overview of the Acucela Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Acucela Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Acucela Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Acucela Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Acucela Inc.'s pipeline products

Reasons to buy

  • Evaluate Acucela Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Acucela Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Acucela Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Acucela Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acucela Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Acucela Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Acucela Inc. Snapshot
    • Acucela Inc. Overview
    • Key Information
    • Key Facts
  • Acucela Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Acucela Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Acucela Inc. - Pipeline Products Glance
    • Acucela Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Acucela Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Acucela Inc. - Drug Profiles
    • emixustat hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Retinopathy of Prematurity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Stargardt Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acucela Inc. - Pipeline Analysis
    • Acucela Inc. - Pipeline Products by Target
    • Acucela Inc. - Pipeline Products by Route of Administration
    • Acucela Inc. - Pipeline Products by Molecule Type
    • Acucela Inc. - Pipeline Products by Mechanism of Action
  • Acucela Inc. - Recent Pipeline Updates
  • Acucela Inc. - Dormant Projects
  • Acucela Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Acucela Inc., Key Information
  • Acucela Inc., Key Facts
  • Acucela Inc. - Pipeline by Indication, 2015
  • Acucela Inc. - Pipeline by Stage of Development, 2015
  • Acucela Inc. - Monotherapy Products in Pipeline, 2015
  • Acucela Inc. - Partnered Products in Pipeline, 2015
  • Acucela Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Acucela Inc. - Phase III, 2015
  • Acucela Inc. - Preclinical, 2015
  • Acucela Inc. - Pipeline by Target, 2015
  • Acucela Inc. - Pipeline by Route of Administration, 2015
  • Acucela Inc. - Pipeline by Molecule Type, 2015
  • Acucela Inc. - Pipeline Products by Mechanism of Action, 2015
  • Acucela Inc. - Recent Pipeline Updates, 2015
  • Acucela Inc. - Dormant Developmental Projects,2015
  • Acucela Inc., Other Locations

List of Figures

  • Acucela Inc. - Pipeline by Top 10 Indication, 2015
  • Acucela Inc. - Pipeline by Stage of Development, 2015
  • Acucela Inc. - Monotherapy Products in Pipeline, 2015
  • Acucela Inc. - Partnered Products in Pipeline, 2015
  • Acucela Inc. - Pipeline by Top 10 Target, 2015
  • Acucela Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Acucela Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Acucela Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top